Indian pharma firm acquires UK’s Actavis to beat Brexit gloom
Beats Mylan, Novartis, Torrent, Aurobindo to the post. Promoter says hungry for more
Almost inarguably, October 5th 2016, a Wednesday was the biggest day in the life of 53 year old Binish Hasmukh Chudgar, the highly low profile vice chairman of Ahmedabad based Intas Pharmaceuticals. That day in central London, Intas snapped up Israeli generic drug maker Teva’s assets in UK and Ireland—Actavis UK Ltd and Actavis Ireland Ltd—in a record $ 764 million deal (Rs 5083 crore) out muscling bigger global rivals like Mylan and Novartis or domestic competition like Aurobindo pharma and Torrent Pharmaceuticals in a bidding process that lasted over 6 months.